Highlights ALK-Abelló A/S

Equities

ALK B

DK0061802139

Real-time Estimate Cboe Europe Other stock markets 04:28:24 2024-07-11 am EDT			5-day change	1st Jan Change
153.1 ^DKK	0.00%		+0.20%	+51.38%

Jun. 21	ALK-Abelló A/S Updates Revenue Guidance for the Year 2024	CI
Jun. 21	ALK Provides Update on Regulatory Process for the House dust Mite Allergy Tablet in China	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ALK-Abelló A/S Updates Revenue Guidance for the Year 2024	Jun. 21	CI
ALK Provides Update on Regulatory Process for the House dust Mite Allergy Tablet in China	Jun. 21	CI
ALK Presents Positive Phase 3 Paediatric Trial Data Offering New Hope for Children with Respiratory Allergy	Jun. 03	CI
Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review	May. 30	CI
ALK-Abelló A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
ALK-Abelló A/S Updates Revenue Guidance for the Year 2024	May. 02	CI
ALK-Abelló A/S Provides Earnings Guidance for the Year 2024	May. 02	CI
New entries in MarketScreener's Europe portfolio	Mar. 04
ALK-Abelló A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024	Feb. 08	CI
Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review	Jan. 25	CI
ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet	Jan. 18	CI
ALK-Abelló Closes Purchase of US Skin Antigen Test Maker AllerQuest	Jan. 04	MT
ALK-Abelló A/S (CPSE:ALK B) acquired Business Assets of AllerQuest.	Jan. 03	CI
ALK-Abelló A/S Expands Partnership with Torii Pharmaceutical Co., Ltd. in Japan	Dec. 12	CI
Alk-Abelló A/S Provides Earnings Guidance for the Year 2023	Nov. 15	CI
ALK-Abelló A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet	23-10-11	CI
ALK-Abelló A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023	23-08-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ALK-Abelló A/S : No allergy on the horizon

March 12, 2024 at 10:20 am EDT